Rankings / Cognitive — Prescription Stimulants
Mazindol ER (Quilience)
Cognitive · Wakefulness / non-amphetamine stimulant (narcolepsy, ADHD)
Tier C+
Bottom line
Read Off Label grades Mazindol ER (Quilience) as C+ (5.5/10) based on moderate evidence, moderate benefit magnitude, and a med-risk safety profile.
NLS Pharmaceutics is reviving mazindol — a 1970s anorectic stimulant — as an extended-release drug (Quilience) for narcolepsy and ADHD.
Studied, labeled, or reported-use context: Oral once daily, extended-release (Phase 2/3 dosing) — Investigational; not individualized guidance.
What the evidence says
NLS Pharmaceutics is reviving mazindol — a 1970s anorectic stimulant — as an extended-release drug (Quilience) for narcolepsy and ADHD. Its mix of dopamine/norepinephrine reuptake inhibition plus partial orexin agonism makes it an unusual non-amphetamine wakefulness/attention agent. The Phase 2 ADHD trial met all primary and secondary endpoints and the FDA cleared the Phase 3 AMAZE narcolepsy program. Another stimulant-alternative to watch, though the orexin agonists (oveporexton) are further along for narcolepsy. Industry-sponsored; pivotal data pending.
Mechanism
Tricyclic agent that inhibits dopamine and norepinephrine reuptake and has partial orexin-receptor agonism; an extended-release reformulation aimed at narcolepsy and ADHD with a smoother profile than classic stimulants
Studied, labeled, or reported dose & route
Oral once daily, extended-release (Phase 2/3 dosing)
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Mazindol ER (Quilience)'s effects?
- Read Off Label rates the evidence for Mazindol ER (Quilience) as Moderate and the benefit magnitude as moderate, producing an overall grade of C+ (5.5/10). NLS Pharmaceutics is reviving mazindol — a 1970s anorectic stimulant — as an extended-release drug (Quilience) for narcolepsy and ADHD.
- What safety findings are reported for Mazindol ER (Quilience)?
- Mazindol ER (Quilience) has a med risk profile in the database. Med (stimulant-class: appetite suppression, insomnia, raised BP/HR; older mazindol was a controlled anorectic, abuse potential lower than amphetamine) Legal status: Investigational (NLS Pharmaceutics; FDA-cleared Phase 3 narcolepsy program; mazindol was a withdrawn anorectic drug).
- What doses or routes are reported for Mazindol ER (Quilience)?
- Oral once daily, extended-release (Phase 2/3 dosing) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Mazindol ER (Quilience) work?
- Tricyclic agent that inhibits dopamine and norepinephrine reuptake and has partial orexin-receptor agonism; an extended-release reformulation aimed at narcolepsy and ADHD with a smoother profile than classic stimulants
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.